Antoni F. Garcia
Lleida, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Real-world evidence of measurable residual disease assessment in multiple myeloma.
Journal: Blood advances
Published: September 18, 2025
Real-world evidence of measurable residual disease assessment in multiple myeloma.
Journal: Blood advances
Published: September 18, 2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
Journal: Blood cancer journal
Published: October 17, 2024
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Journal: European journal of haematology
Published: June 23, 2022
Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation.
Journal: Bone marrow transplantation
Published: December 12, 2021
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
Journal: Blood advances
Published: December 30, 2020
Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma.
Journal: Leukemia & lymphoma
Published: September 16, 2020
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Journal: Annals of hematology
Published: September 06, 2020
Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes.
Journal: Leukemia research
Published: August 12, 2020
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Journal: Clinical epigenetics
Published: July 15, 2020
Last Updated: 09/26/2026